Is The Downturn A ‘Darwinian Moment’ For Biotech? The View From The Frontline
Cutbacks And Threat Of Closure Hitting Small To Medium Biotechs
After the boom of 2020 and 2021, the biotech sector is experiencing one of the deepest and longest downturns but there are hopes that catalysts could soon revive confidence.
You may also be interested in...
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
HealthCap’s Steen On Growing Successful Precision Medicine Businesses
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
Blueprint And Ardelyx Join List Of Biotechs Selling Royalties To Raise Funds
The US firms have added to a growing number of struggling biotech companies that are selling off future royalties to help push promising drug candidates past the finish line.